Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Histiocytic Disorders, Malignant | 3 | 2025 | 4 | 1.680 |
Why?
|
| Erdheim-Chester Disease | 7 | 2020 | 8 | 1.390 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2024 | 23 | 1.060 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 355 | 0.870 |
Why?
|
| Lymphadenopathy | 1 | 2023 | 20 | 0.820 |
Why?
|
| Splenic Neoplasms | 1 | 2022 | 18 | 0.800 |
Why?
|
| Lymphoma, B-Cell | 1 | 2022 | 109 | 0.730 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2020 | 154 | 0.590 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2024 | 31 | 0.550 |
Why?
|
| Seroma | 1 | 2016 | 7 | 0.530 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2016 | 9 | 0.520 |
Why?
|
| Dermatomyositis | 1 | 2016 | 18 | 0.520 |
Why?
|
| Drug Discovery | 1 | 2017 | 110 | 0.510 |
Why?
|
| Protein Kinases | 1 | 2017 | 215 | 0.500 |
Why?
|
| Calcinosis | 1 | 2016 | 230 | 0.460 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1576 | 0.440 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 598 | 0.410 |
Why?
|
| Histiocytosis | 3 | 2019 | 7 | 0.340 |
Why?
|
| Mutation | 7 | 2024 | 4204 | 0.340 |
Why?
|
| Lymphoma, T-Cell | 2 | 2020 | 59 | 0.320 |
Why?
|
| Neoplasms | 1 | 2023 | 3117 | 0.280 |
Why?
|
| Humans | 26 | 2025 | 92337 | 0.270 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2023 | 815 | 0.270 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2023 | 59 | 0.260 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2368 | 0.250 |
Why?
|
| Langerhans Cells | 1 | 2023 | 14 | 0.210 |
Why?
|
| Dendritic Cells | 2 | 2024 | 455 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 183 | 0.200 |
Why?
|
| Cyclin D3 | 1 | 2022 | 21 | 0.200 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2019 | 39 | 0.200 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2023 | 163 | 0.190 |
Why?
|
| Middle Aged | 11 | 2024 | 27030 | 0.190 |
Why?
|
| Myeloproliferative Disorders | 1 | 2023 | 139 | 0.190 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2021 | 24 | 0.180 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2021 | 39 | 0.180 |
Why?
|
| Plasma Cells | 1 | 2021 | 86 | 0.180 |
Why?
|
| Flow Cytometry | 2 | 2020 | 704 | 0.170 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2020 | 6 | 0.170 |
Why?
|
| MAP Kinase Signaling System | 2 | 2019 | 200 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 2556 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2023 | 552 | 0.160 |
Why?
|
| Azetidines | 1 | 2019 | 37 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 159 | 0.150 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1807 | 0.150 |
Why?
|
| Female | 13 | 2024 | 47893 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6916 | 0.150 |
Why?
|
| Aged | 8 | 2024 | 19943 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 98 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 183 | 0.150 |
Why?
|
| Adult | 9 | 2024 | 27532 | 0.150 |
Why?
|
| Oximes | 1 | 2018 | 17 | 0.150 |
Why?
|
| Piperidines | 1 | 2019 | 164 | 0.140 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2017 | 16 | 0.140 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2017 | 4 | 0.140 |
Why?
|
| Erythroid Precursor Cells | 1 | 2017 | 33 | 0.140 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2017 | 18 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 166 | 0.140 |
Why?
|
| Imidazoles | 1 | 2018 | 141 | 0.140 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2017 | 30 | 0.140 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1592 | 0.140 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 51 | 0.130 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2016 | 13 | 0.130 |
Why?
|
| Lymphadenitis | 1 | 2016 | 7 | 0.130 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 132 | 0.130 |
Why?
|
| ras Proteins | 1 | 2017 | 133 | 0.130 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 33 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2017 | 228 | 0.130 |
Why?
|
| Breast Implants | 1 | 2016 | 27 | 0.130 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 264 | 0.130 |
Why?
|
| Male | 10 | 2024 | 43925 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 310 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2018 | 425 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 680 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 1150 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 1247 | 0.090 |
Why?
|
| Immunophenotyping | 2 | 2024 | 222 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2017 | 2978 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2020 | 139 | 0.080 |
Why?
|
| Young Adult | 4 | 2024 | 6624 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2021 | 358 | 0.070 |
Why?
|
| HIV Infections | 1 | 2016 | 895 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2017 | 3508 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2021 | 9703 | 0.060 |
Why?
|
| Child | 3 | 2023 | 7334 | 0.060 |
Why?
|
| Phenotype | 2 | 2023 | 2498 | 0.060 |
Why?
|
| GATA3 Transcription Factor | 1 | 2024 | 52 | 0.060 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2023 | 3 | 0.060 |
Why?
|
| Blood Platelet Disorders | 1 | 2023 | 12 | 0.050 |
Why?
|
| Macrophages | 2 | 2017 | 599 | 0.050 |
Why?
|
| Thrombopoiesis | 1 | 2023 | 5 | 0.050 |
Why?
|
| Cyclin D1 | 1 | 2021 | 84 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2021 | 262 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2023 | 468 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 1119 | 0.040 |
Why?
|
| Cerebellar Ataxia | 1 | 2020 | 24 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2020 | 106 | 0.040 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2020 | 142 | 0.040 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 15 | 0.040 |
Why?
|
| Transcriptome | 1 | 2024 | 699 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 89 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2019 | 48 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 1477 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 341 | 0.040 |
Why?
|
| Mosaicism | 1 | 2017 | 71 | 0.030 |
Why?
|
| Clone Cells | 1 | 2017 | 214 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 122 | 0.030 |
Why?
|
| Dioxygenases | 1 | 2017 | 79 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2017 | 161 | 0.030 |
Why?
|
| Microglia | 1 | 2017 | 109 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2021 | 8740 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 289 | 0.030 |
Why?
|
| Adolescent | 2 | 2020 | 9504 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 370 | 0.030 |
Why?
|
| Monocytes | 1 | 2017 | 223 | 0.030 |
Why?
|
| Animals | 3 | 2023 | 28003 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 100 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 291 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1592 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1398 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1141 | 0.030 |
Why?
|
| Mice | 2 | 2017 | 12110 | 0.030 |
Why?
|
| Prevalence | 1 | 2017 | 1294 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 1312 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 4468 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2448 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3509 | 0.020 |
Why?
|